AcquisitionsJul 31, 2026, 05:02 PM
Profusa Signs Option Agreement to Acquire G3 Vision Labs
AI Summary
Profusa, Inc. entered into an Option Agreement to acquire G3 Vision Labs Inc. and its subsidiaries, Med Screen Laboratories Inc., Dominion Diagnostics LLC, and Acutis Diagnostics Inc. The agreement grants Profusa the right, but not the obligation, to acquire 100% of G3's equity securities. The exercise of this option is subject to several conditions, including Profusa securing at least $30 million in financing and obtaining stockholder approvals. As consideration for the option, Profusa issued common stock and Series A Non-Voting Convertible Preferred Stock to G3's sellers. G3's 2025 net revenues are estimated at $111 million.
Key Highlights
- Profusa signed an Option Agreement to acquire G3 Vision Labs and its subsidiaries.
- G3 Vision Labs' 2025 estimated net revenues are approximately $111 million.
- Profusa must secure at least $30 million in financing to exercise the option.
- The option exercise is subject to Profusa stockholder approval for preferred stock conversion.
- Consideration for the option included 201,120 shares of Profusa common stock.
- Consideration also included 52,903.566 shares of Series A Non-Voting Convertible Preferred Stock.
- If the option is exercised, an additional 53,918.113 shares of Series A Preferred Stock will be issued.
- Each Series A Preferred Stock share is convertible into 1,000 shares of common stock.
Price Impact
More from PFSA